Propanc Biopharma is advancing a novel therapeutic approach that leverages pancreatic proenzymes to eradicate cancer stem cells responsible for the spread and return of solid tumors. Its lead product candidate is being developed for pancreatic, ovarian, and colorectal cancers, aiming to halt metastasis by exploiting the body’s natural enzyme defense mechanisms. The company plans to use newly secured capital to accelerate its clinical pipeline and simultaneously build a Digital Asset Treasury, targeting a portfolio valued at $100 million within twelve months. Management believes the rise of Digital Asset Treasury (DAT) companies presents an additional avenue for shareholder value creation. While no revenue or user metrics were disclosed, Propanc highlights the strategic importance of its pipeline progress and treasury strategy. Headquartered in Melbourne, the firm positions itself at the intersection of oncology therapeutics and digital asset finance, seeking both short- and long-term growth.

Total raised

$1M

Funding rounds

1

Latest round

Series C

Latest activity

Oct 2025